Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

NCT00450944 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins

Sponsor

Albert Einstein College of Medicine

Collaborators

[object Object]